Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne, Denis G Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K Chang, Robert B Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S Gail Eckhardt, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika A Jarzabek, Steven de JongJos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G Palmer, Daniel S Peeper, Pier Giuseppe Pelicci, Alejandro Piris-Gimenez, Sergio Roman-Roman, Oscar M Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti, Livio Trusolino

Research output: Contribution to journal/periodicalArticleScientificpeer-review

506 Citations (Scopus)

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

Original languageEnglish
Pages (from-to)254-268
Number of pages15
JournalNature reviews. Cancer
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Animals
  • Biomarkers, Tumor
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Drug Resistance, Neoplasm
  • Humans
  • Immunotherapy
  • Mice
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplastic Stem Cells
  • Precision Medicine
  • Xenograft Model Antitumor Assays
  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Interrogating open issues in cancer precision medicine with patient-derived xenografts'. Together they form a unique fingerprint.

Cite this